Vyvanse Dosing for ADHD
For ADHD treatment, start Vyvanse at 30 mg once daily in the morning for all patients aged 6 years and older (children, adolescents, and adults), titrate weekly by 10-20 mg increments as needed, and do not exceed the maximum dose of 70 mg/day. 1
Starting Dose
- All age groups (≥6 years): 30 mg once every morning 1
- Take in the morning regardless of meals
- Same starting dose applies to children (6-12 years), adolescents (13-17 years), and adults
Titration Schedule
- Increase by 10 mg or 20 mg weekly based on clinical response and tolerability 1
- Assess efficacy using parent and teacher rating scales (ADHD-RS-IV) for children/adolescents
- For adults, obtain self-ratings and reports from significant others
- Continue titration until optimal symptom control is achieved with tolerable side effects
Target Therapeutic Range
- Recommended dose range: 30-70 mg/day 1
- Most patients respond within this range
- Clinical trials demonstrated efficacy across all doses (30,50, and 70 mg) with significant improvements in ADHD symptoms 1, 2
Maximum Dose
- Standard maximum: 70 mg/day for all patients 1
- Severe renal impairment: Maximum 50 mg/day 1
- End-stage renal disease (ESRD): Maximum 30 mg/day 1
Duration of Effect
Vyvanse provides full-day coverage up to 13-14 hours post-dose, with efficacy demonstrated from 1.5 hours through 13 hours in laboratory school studies 3. This once-daily dosing eliminates the need for school-time administration, a significant practical advantage over immediate-release stimulants.
Key Clinical Considerations
Pre-treatment assessment:
- Obtain baseline blood pressure, pulse, height, and weight 4
- Screen for cardiac disease before initiating treatment 1
- Document prior medication trials and responses
Monitoring during titration:
- Weekly contact (office visit or telephone) during dose adjustments 4
- Titration phase typically requires 2-4 weeks
- Systematically assess for common side effects: decreased appetite (39-47%), insomnia (19-27%), headache, upper abdominal pain, and irritability 5, 2
Maintenance phase:
- Monthly follow-up appointments until symptoms stabilized 4
- Monitor weight at each visit as objective measure of appetite effects
- Adults should have blood pressure and pulse checked quarterly 4
Important Caveats
The 2019 AAP guidelines strongly recommend FDA-approved ADHD medications for children ≥6 years, preferably combined with behavioral interventions 6. While older 2002 guidelines discuss general amphetamine dosing starting at 2.5 mg 4, these predate Vyvanse's approval and are superseded by the FDA-approved dosing for this specific prodrug formulation.
Vyvanse is NOT recommended for preschool-aged children (4-5 years), where parent training and behavioral interventions are first-line, with methylphenidate considered only if behavioral treatments fail 6.
The prodrug formulation of Vyvanse provides gradual release of d-amphetamine through rate-limited hydrolysis, which may reduce abuse potential compared to immediate-release amphetamines while maintaining consistent therapeutic effect throughout the day 7, 8.